North America Bloodstream Infection Testing Market (By Product: Instruments, Reagents & Consumables; By Sample Type; By Technology; By End-user) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The North America bloodstream infection testing market size was estimated at around USD 318.19 million in 2023 and it is projected to hit around USD 454.07 million by 2033, growing at a CAGR of 3.62% from 2024 to 2033.

Key Pointers

• By Product, the reagents and consumables segment generated the maximum market share of 90% in 2023.
• By Sample Type, the blood culture segment accounted for the largest revenue share of 76% in 2023.
• By Technology, the PCR segment held the largest revenue share of 61% in 2023.
• By End-user, the hospital and diagnostic centers segment contributed the largest market share of 46% in 2023.

North America Bloodstream Infection Testing Market Overview

The North America bloodstream infection testing market stands at the forefront of diagnostic advancements, propelled by the imperative need for accurate and timely identification of bloodstream infections (BSIs). Bloodstream infections, a significant cause of morbidity and mortality, require swift diagnosis and intervention for effective patient management. 

North America Bloodstream Infection Testing Market Growth Factors 

The growth of the North America bloodstream infection testing market is driven by an increasing incidence of bloodstream infections, driven by factors such as the aging population, rising prevalence of chronic diseases, and widespread use of invasive medical procedures, necessitates enhanced diagnostic capabilities. Additionally, growing awareness among healthcare professionals regarding the importance of early detection and prompt intervention for bloodstream infections contributes to market expansion. Moreover, technological advancements in diagnostic methodologies, including molecular diagnostics and rapid blood culture systems, enable clinicians to achieve faster and more accurate diagnoses, further propelling market growth. 

Report Scope of the North America Bloodstream Infection Testing Market

North America Bloodstream Infection Testing Market Trends:

• Adoption of Point-of-Care Testing (POCT): There is a growing trend towards the adoption of point-of-care testing solutions for bloodstream infections in North America. POCT offers several advantages, including rapid results, which facilitate timely clinical decision-making and improved patient management. This trend is driven by the increasing demand for decentralized testing options that enable quick diagnosis and treatment initiation.
• Integration of Artificial Intelligence (AI) and Machine Learning (ML): The integration of artificial intelligence and machine learning algorithms into bloodstream infection testing platforms is a notable trend in North America. These technologies enhance the accuracy and efficiency of diagnostic processes by analyzing complex data patterns and identifying relevant biomarkers. AI and ML-powered solutions enable clinicians to make more informed decisions and optimize patient care pathways.
• Rise of Multiplex Testing: Multiplex testing, which allows simultaneous detection of multiple pathogens in a single sample, is gaining traction in the North America bloodstream infection testing market. This trend is driven by the increasing recognition of the polymicrobial nature of bloodstream infections and the need for comprehensive pathogen identification. Multiplex testing offers advantages such as improved sensitivity and specificity, reduced turnaround time, and cost-effectiveness, thereby enhancing diagnostic capabilities.
• Focus on Personalized Medicine: There is a growing focus on personalized medicine in the North America bloodstream infection testing market, driven by advancements in genomic and molecular diagnostics. Personalized medicine approaches enable tailored treatment strategies based on individual patient characteristics, including pathogen susceptibility profiles and host factors. This trend facilitates precision diagnosis and targeted antimicrobial therapy, leading to improved clinical outcomes and reduced antimicrobial resistance.

Product Insights

The reagents and consumables segment accounted for the largest revenue share of 90% in 2023. The segment is also expected to expand at the fastest growth rate over the forecast period. The segment's growth is driven by the easy availability and frequent purchase of screening products for donors and recipients. Moreover, the market is propelled by the wide range of blood grouping, typing, and donor screening reagents, kits, and assays offered by North American and local manufacturers.

Additionally, the expanding product portfolio caters to the diverse needs of healthcare facilities, further fueling the growth of the segment in the regional bloodstream infection testing market. For instance, in March 2022, Accelerate Diagnostics, Inc., an in-vitro diagnostics company, launched the Accelerate Arc system. It comprises the Accelerated Arc Module and blood culture (BC) kit, an automated path for the accurate and rapid microbial recognition of positive blood cultures.

Sample Type Insights

The blood culture segment accounted for the largest revenue share of 76% in 2023 and is expected to witness the fastest CAGR over the forecast period. Blood culture testing has continued to evolve with technological advancements. The introduction of automated blood culture systems and faster detection methods have enhanced result efficiency and turnaround time, further cementing the segment’s dominance.

For instance, in October 2022, BD, a global medical technology company, and Magnolia Medical Technologies, Inc. entered a commercial agreement. The collaboration aims to assist U.S. hospitals in reducing blood culture contamination, enhancing testing accuracy, and ultimately improving clinical outcomes. Therefore, such initiatives with effective tools and technologies enhance the reliability and efficiency of blood culture testing, thereby boosting the demand for such methods.

Moreover, the blood culture segment is expected to experience growth due to the increasing number of cancer cases, bloodstream infections (BSIs), and sepsis. For instance, in June 2021, Accelerate Diagnostics, a biotech company based in Tucson, Arizona, USA, was granted funding of USD 578,000 by CARB-X. The funds are specifically allocated for developing innovative fiber optic technology aimed at diagnosing sepsis or assessing the risk of sepsis. This financial support signifies a significant opportunity for the company to advance its sepsis diagnostic capabilities and contribute to improving patient outcomes.

Technology Insights

The PCR segment held the largest revenue share of 61% in 2023 in the North America bloodstream infection testing market and is expected to expand at the fastest CAGR over the forecast period. The introduction of technologically advanced PCR tests, government initiatives, increasing prevalence of targeted diseases, and application expansion of existing technologies are expected to drive segment growth over the forecast period.

For instance, PLEX-ID (Abbott Molecular) is an advanced multiplex real-time automated PCR system with amplicon product detection using ESI MS technology. This innovative solution enables rapid and accurate genotypic characterization of various pathogens, including bacteria, fungi, viruses, and parasites within a given sample, such as cultures or whole blood. By utilizing broad-range primers targeting pathogen groups instead of specific species, PLEX-ID provides comprehensive and efficient identification capabilities. This advanced technology strengthens diagnostic capabilities in infectious disease management, offering businesses a valuable tool to enhance patient care and streamline laboratory workflows, thereby fueling segment growth.

End-user Insights

The hospital and diagnostic centers segment accounted for the largest revenue share of 46% in 2023 and is expected to witness the fastest CAGR from 2024 to 2033. Hospitals often have R&D departments dedicated to studying bloodstream infections and developing new diagnostic tools, therapies, and preventive strategies. Their expertise and resources contribute to advancements in the field, further solidifying their position in the bloodstream infection testing market. Hospitals also possess advanced healthcare infrastructure, including well-equipped laboratories, diagnostic facilities, and skilled healthcare professionals. This allows for efficient diagnosis, monitoring, and treatment of bloodstream infections, leading to better patient outcomes.

Moreover, hospitals frequently collaborate with medical device manufacturers, pharmaceutical companies, and diagnostic companies to develop and test innovative solutions for bloodstream infection management. These collaborations ensure the availability of advanced products and technologies within the hospital setting, strengthening their dominance in the market. In addition, advanced infrastructure, infection control measures, research capabilities, and collaborations with industry contribute to their dominant position in the bloodstream infection testing market in the region.

North America Bloodstream Infection Testing Market Key Companies

• bioMérieux SA
• BD
• Cepheid
• Seegene Inc.
• Abbott
• F. Hoffmann-La Roche Ltd
• Siemens Healthcare Limited
• Luminex Corporation
• Bruker
• Accelerate Diagnostics, Inc.

North America Bloodstream Infection Testing Market Segmentations:

By Product 

• Reagents & Consumables
• Instruments

By Sample Type 

• Whole Blood
• Blood Culture

By Technology 

• PCR
• Mass Spectroscopy
• In Situ Hybridization
• Others

By End-user 

• Hospitals & Diagnostic Centers
• Custom Laboratory Service Providers
• Academic & Research Institutes
• Others